Abstract 5250: Method development and workflow optimization of a CTC-based biomarker assay to predict response to CDK4/6 inhibitors in HR+/HER2- breast cancer
Mantasha Tabassum(University of Houston), Meghana V. Trivedi(University of Houston), Mothaffar F. Rimawi(Baylor College of Medicine), Wangjia Cao(University of Houston), Shivaani Suresh Kanna(University of Houston), Suneel Kumar(Baylor College of Medicine), George Miles(Baylor College of Medicine)
Cited by 0
Related Papers
Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function
|Cancer Research|2008|494
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
|Clinical Cancer Research|2013|273
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial
|Journal of Clinical Oncology|2018|233
Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize
|Cancer Research|2018|221